Vanta Bioscience Stock Screener | Share Price & Fundamental Analysis
VANTABIO
Healthcare Technology
Screen Vanta Bioscience share price with our stock screener - analyze fundamentals and track trades in your journal
Market Cap
₹16.70 Cr.
P/B Ratio
1.16
EPS (TTM)
₹-7.56
Dividend Yield
-
Debt to Equity
5.11
52W High
-
52W Low
-
Operating Margin
-206.00%
Profit Margin
-100.00%
Revenue (TTM)
₹1.00
EBITDA
₹-1.00
Net Income
₹-1.00
Total Assets
₹86.00
Total Equity
₹4.00
Vanta Bioscience Share Price History - Stock Screener Chart
Screen VANTABIO historical share price movements with interactive charts. Analyze price trends and patterns.
Vanta Bioscience Company Profile - Fundamental Screener
Screen Vanta Bioscience company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for VANTABIO shares.
Sector
Healthcare
Industry
Healthcare Technology
Sub-Sector
Healthcare Technology
Segment
E
ISIN
INE695X01011
Vanta Bioscience Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen VANTABIO balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Total Assets | 86 | 85 | 85 | 81 | 70 | 49 | 39 |
| Current Assets | 15 | 17 | 15 | 15 | 20 | 20 | 17 |
| Fixed Assets | 56 | 54 | 57 | 36 | 29 | 21 | 18 |
| Liabilities | |||||||
| Total Liabilities | 86 | 85 | 85 | 81 | 70 | 49 | 39 |
| Current Liabilities | 56 | 50 | 48 | 34 | 29 | 14 | 13 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | |||||||
| Total Equity | 4 | 13 | 19 | 29 | 26 | 25 | 23 |
| Share Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Reserves & Surplus | 4 | 9 | 11 | 18 | 18 | 17 | 16 |
Screen VANTABIO income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2023-Mar | 2022-Dec | 2022-Mar | 2021-Dec |
|---|---|---|---|---|
| Revenue | 1 | 3 | 5 | 0 |
| Expenses | 2 | 3 | 2 | 0 |
| EBITDA | -1 | -1 | 2 | 0 |
| Operating Profit % | -206.00% | -20.00% | 46.00% | 0.00% |
| Depreciation | 0 | 1 | 1 | 0 |
| Interest | 1 | 3 | 1 | 0 |
| Profit Before Tax | -2 | -4 | 1 | 0 |
| Tax | 0 | -2 | 0 | 0 |
| Net Profit | -1 | -3 | 0 | 0 |
| EPS | 0.00 | -4.06 | 0.11 | 0.00 |
Vanta Bioscience Cash Flow Screener - Liquidity Fundamentals
Screen VANTABIO cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March |
|---|---|---|---|---|---|---|---|
| Operating Activities | -2 | 3 | -1 | 5 | 7 | 2 | -1 |
| Investing Activities | -7 | -3 | -6 | -17 | -22 | -8 | -6 |
| Financing Activities | 9 | 1 | 6 | 10 | 18 | 2 | 10 |
| Net Cash Flow | 0 | 0 | 0 | -2 | 3 | -3 | 3 |
Screen VANTABIO shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Sept | 2024-Mar | 2023-Sept | 2023-Mar | 2022-Sept |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 72.81% | 72.81% | 69.36% | 69.36% | 69.36% | 69.36% | 69.36% | 69.36% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 23.66% | 23.39% | 26.35% | 26.55% | 25.97% | 26.77% | 26.77% | 26.56% |
| Other Holding | 3.53% | 3.81% | 4.29% | 4.09% | 4.67% | 3.87% | 3.87% | 4.08% |
| Shareholder Count | 419 | 408 | 408 | 424 | 418 | 388 | 394 | 393 |
Vanta Bioscience Dividend Screener - Share Yield Analysis
Screen VANTABIO dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
Vanta Bioscience Index Membership - Market Screener Classification
Screen VANTABIO by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Vanta Bioscience Market Events Screener - Corporate Actions
Screen VANTABIO market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | 9.19% | ||
| Annual General Meeting | NA | 4.98% | ||
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | -5.00% |
| 2025-08-01 | 2025-08-01 | Quarterly Result Announcement | NA | 18.62% |
| 2025-01-04 | 2025-01-04 | Extraordinary General Meeting | NA | -2.97% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -9.75% |
Vanta Bioscience Competitors Screener - Peer Comparison
Screen VANTABIO competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Syngene International | 26,310 | 55.90 | 3,714 | 3.77% | 496 | 51.46 |
| Indegene | 12,606 | 28.01 | 2,947 | 10.53% | 407 | 42.94 |
| Suven Life Sciences | 3,776 | -17.74 | 18 | -46.34% | -161 | 39.99 |
| Vimta Labs | 2,713 | 43.62 | 322 | 0.22% | 41 | 44.90 |
| Take Solutions | 601 | 12.37 | 10 | 126.67% | 1 | 87.87 |
| Bilcare | 185 | -4.17 | 807 | 4.78% | -56 | 43.28 |
| Jeevan Scientific Technology | 103 | -22.71 | 48 | 17.87% | 0 | 62.49 |
| Adeshwar Meditex | 26 | 33.09 | 84 | 5.00% | 2 | 21.16 |
| Vanta Bioscience | 17 | -1.26 | 2 | -78.57% | -13 | 20.40 |
Vanta Bioscience Company Announcements - News Screener
Screen VANTABIO latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2025-11-14 | Financial Results For The Half Year Ended September 30 2025 | View |
| 2025-11-14 | Board Meeting Outcome for Outcome Of The Board Meeting Held On November 14 2025 | View |
| 2025-11-08 | Board Meeting Intimation for Board Meeting To Be Held On 14.11.2025 | View |
| 2025-11-01 | Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer | View |
| 2025-11-01 | Reg. 34 (1) Annual Report. | View |
| 2025-10-03 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | View |
| 2025-09-30 | Shareholder Meeting / Postal Ballot-Outcome of AGM | View |
| 2025-09-30 | Closure of Trading Window | View |
| 2025-09-06 | Board Meeting Outcome for Outcome Of Board Meeting Held On 06.09.2025 | View |
| 2025-08-01 | Financials For The Half Year And Year Ended 31.03.2025 | View |
| 2025-08-01 | Board Meeting Outcome for Outcome Of The Board Meeting Held On 01.08.2025 | View |
| 2025-07-29 | Board Meeting Intimation for Postponement Of Board Meeting To August 01 2025 | View |
| 2025-07-26 | Board Meeting Intimation for Postponement Of Board Meeting To July 29 2025 | View |
| 2025-07-19 | Board Meeting Intimation for Postponement Of Board Meeting Scheduled On July 19 2025 And Will Now Be Held On Thursday July 24 2025 | View |
| 2025-07-16 | Board Meeting Intimation for Board Meeting To Be Held On July 19 2025 | View |
| 2025-06-16 | Rejection Of Promoter Reclassification Application | View |
| 2025-05-29 | Cancellation of Board Meeting | View |
| 2025-05-29 | Results-Delay in Financial Results | View |
| 2025-05-21 | Board Meeting Intimation for Board Meeting On 30/05/2025 | View |
| 2025-05-09 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | View |